The Carelon "ghost network" case just survived — and the payer industr – Good Machine

TL;DR

A federal judge in the Southern District of New York issued a 1 April 2026 ruling allowing most claims to proceed in a case against Carelon, the Elevance Health behavioural health subsidiary, alleging systematic misrepresentation of mental-health provider network adequacy (the "ghost network" allegation).
Surviving the motion-to-dismiss stage matters: it means the plaintiffs' theory — that listed network providers were unreachable, not accepting new patients, or no longer in network — has been deemed plausible enough to test on the evidence.
The case is one of several federal actions on parity-act and network-adequacy grounds against major payers' behavioural-health units. A win or material settlement here is industry precedent.
The clinical and operational reality the case captures is widely acknowledged: behavioural-health network directories overstate effective access, particularly for in-network psychiatrists, child psychiatrists, and substance-use disorder providers. The MHPAEA enforcement framework has historically lacked teeth; this case is a test of whether civil litigation can do what regulation has not.
The decision-useful framing for employers, plan sponsors, and clinical leaders: the question of what does your effective behavioural-health network actually look like is now a legal and reputational question, not just a quality-improvement one.

What the ruling actually does

The 1 April ruling, issued in the Southern District of New York, addressed Carelon's (formerly Beacon Health Options, now an Elevance Health subsidiary) motion to dismiss in a case brought by plaintiffs alleging that Carelon's published mental-health provider networks systematically misrepresented the availability of in-network providers.

The judge allowed the majority of claims to proceed past the motion-to-dismiss stage. That means the court found the plaintiffs' factual allegations and legal theories — predominantly grounded in the Mental Health Parity and Addiction Equity Act (MHPAEA), state insurance and consumer-protection law, and ERISA fiduciary duties — sufficient to warrant a full evidentiary hearing.

The "ghost network" theory is straightforward. A payer's directory lists in-network providers. Patients call those providers and find that they are not actually accepting new patients, are not actually in network, are not reachable, are no longer in practice, or are otherwise not effectively available. The directory is the basis on which patients believe they have access; the lived reality is materially different.

Several earlier studies — including a 2023 federal "secret shopper" investigation, multiple state-level audits, and academic analyses — have documented this pattern at scale. The Carelon case turns those documented patterns into a specific civil claim against a specific payer's behavioural-health subsidiary.

What it actually means

The ruling matters at three layers.

At the doctrinal layer. Surviving motion-to-dismiss in this type of case is non-trivial. Defendants have historically argued that network-adequacy requirements are regulatory, not actionable, and that directory information is not the basis for a private right of action. The 1 April ruling rejects enough of that argument to let plaintiffs build a case on the evidence. If the plaintiffs can prove their factual claims at trial — or if Carelon settles to avoid that — the precedent will affect how every commercial payer's behavioural-health subsidiary defends similar claims going forward.

At the operational layer. Network-adequacy auditing is the function inside payer organisations that would have to change. The current model — periodic provider attestations, sample directory verification, regulatory filings — has produced the gap the plaintiffs are suing over. A meaningful settlement or judgment forces a step-change in network management, with the cost falling on the payer's behavioural-health unit.

At the policy layer. MHPAEA enforcement has been the lever federal regulators have used since 2008, and the consensus view of clinicians, advocates, and policy researchers is that enforcement has not produced the access reality the law promised. Civil litigation is now the parallel pathway. If it works here, it will work elsewhere.

The patient-impact reality underneath the case is genuinely serious. The behavioural-health workforce shortage is real — there are not enough psychiatrists, child psychiatrists, and addiction specialists to meet demand even if every directory listing were accurate. The "ghost network" problem compounds the workforce shortage by misrepresenting the situation: patients who would otherwise know to look elsewhere instead spend weeks on a phone tree.

Hype deconstruction

The case is not yet won. Surviving motion-to-dismiss is a procedural threshold, not a verdict. The plaintiffs still have to prove their factual claims at trial or negotiate a settlement. Carelon and Elevance will mount substantial defence. The case could resolve in any direction.

It is not the only such case. Several similar actions are pending against other major payers' behavioural-health units. The Carelon ruling will likely affect those cases procedurally, but it does not automatically determine their outcomes.

It is not the only path forward. The Departments of Labor, Health and Human Services, and Treasury issued a joint final rule on MHPAEA enforcement in 2024 that, in principle, gives federal regulators stronger tools. The civil-litigation pathway is one of several pressure points; the regulatory pathway is another; state-level enforcement is a third.

The "ghost network" framing is broadly correct, but the diagnosis is more complex. The phenomenon includes some genuine bad-faith directory misrepresentation. It also includes: providers leaving networks faster than directories update, providers practising at full capacity who decline new patients without informing the payer, payer-clinician contracting friction that puts providers in ambiguous in-network status, and pure workforce shortages where there is nobody to call. Litigation against payers can address the first; the others require different interventions.

What is not hype. The patient experience is well-documented and bad. Multiple peer-reviewed studies have found that fewer than half of listed mental-health providers are effectively reachable and accepting patients within reasonable time-and-distance criteria. The lived reality the case alleges is the lived reality the literature describes.

Stakeholder landscape

Patients seeking behavioural-health care. The most-affected group. The case's progression will not change this week's experience but, over a multi-year horizon, may change the directory accuracy and accountability standard.

Major commercial payers' behavioural-health units. Carelon (Elevance), Optum Behavioral Health (UnitedHealth), Magellan Healthcare (Centene), Evernorth Behavioral Health (Cigna). Each is exposed to similar civil-litigation risk and to enhanced regulatory scrutiny.

Self-insured employers. ERISA fiduciary duty includes duty of care in selecting and monitoring health-plan vendors. Plan sponsors have an interest in their TPA's behavioural-health network actually working as represented; the case sharpens that interest.

Behavioural-health providers. A growing share of psychiatrists are operating cash-pay or out-of-network because in-network economics are unfavourable. The provider-side response to litigation pressure on payers will be a critical determinant of whether the case produces actual access improvement or just better directory hygiene.

State insurance regulators. California, New York, Washington, Massachusetts, and Oregon have led on network-adequacy regulation. Each will be watching the federal litigation alongside their own enforcement programmes.

Class-action plaintiffs' bar. A favourable Carelon outcome creates a template for similar cases against other behavioural-health units. Litigation pipeline development will accelerate.

Mental-health advocacy. Mental Health America, NAMI, the Kennedy-Satcher Center, and the parity-act focused advocacy organisations have been pushing for stronger enforcement for years. The case's progression is a moment of validation for that work.

Cross-layer implications

Network management technology. Real-time directory verification, provider availability APIs, and patient-experience monitoring infrastructure are areas where investment will accelerate. Several start-ups (Quartet, Lyra, others) operate in this space; their value proposition just got sharper.
MHPAEA regulatory enforcement. The 2024 final rule's enforcement architecture is in early implementation. The Carelon case provides additional momentum for federal agencies to use the new tools more aggressively.
Provider-side economics. If payers face pressure to actually have functional networks, in-network behavioural-health rates need to rise to attract and retain providers. The cost-side implication for payers is meaningful.
Tele-behavioural-health. Tele-mental-health platforms (Talkspace, BetterHelp, Headspace Health, Lyra) operate adjacent to the network-adequacy question. If commercial payers' in-person networks remain inadequate, virtual-first behavioural-health gets more strategic.
Self-insured employer plan design. Plan sponsors with in-house claims oversight (large employers, multi-employer trusts) have increasing visibility into their TPA's behavioural-health network performance. Expect plan-design changes — direct contracting with behavioural-health providers, employer-sponsored EAP integration, enhanced virtual access — as a response.
State legislation. California's network-adequacy enforcement has been the most active. Other states may follow with parallel state-level statutes that go further than MHPAEA.

What this means for you

Patients. Two practical points. First, document. If you encounter a directory listing that is not effective access, log it — date, provider name, what happened on the call. State insurance regulators take complaints seriously, and documented patterns are how enforcement happens. Second, escalate. Your plan's appeals process, your employer's HR, and state regulator complaint channels are available. The mental-health-parity protections exist; the channels work better when used.

Self-insured employer benefits leaders. This is now an ERISA fiduciary issue, not just a vendor-quality issue. Begin asking your TPA for verified network-adequacy reporting — not directory counts, verified-effective-access numbers from secret-shopper or other methodologically robust sampling. If your TPA cannot provide it, that is itself a finding.

Behavioural-health clinical leaders. The system-level access problem is upstream of any individual practice. The contribution clinical leaders can make is on the supply side: residency expansion, scope-of-practice modernisation for psychiatric NPs and behavioural-health-trained primary-care, telehealth deployment, and the workforce pipeline conversation. Litigation will pressure payers; only workforce expansion ultimately fixes access.

Payer organisations. The defensible operational response is a serious upgrade to network-adequacy verification — quarterly secret-shopper sampling, provider-availability API integration, automated directory hygiene, and external auditor sign-off. The costly response is doing nothing and waiting for a successor case to land badly. The choice is now legal-defensibility-driven, not just quality-improvement-driven.

State and federal regulators. The civil-litigation pathway is doing some of the work that MHPAEA enforcement was supposed to do. The regulatory question is whether to lean into that — coordinated investigation, joint enforcement actions, support for class-action evidence — or to view it as parallel and unrelated. Coordinated approaches will get more done than siloed ones.

Investors. Watch the Carelon and Elevance equity reaction. Watch the broader commercial-payer behavioural-health-unit valuation. Network-management technology vendors get more interesting. Tele-behavioural-health platforms get more interesting. The legal-services-and-litigation infrastructure layer is the third-order opportunity.

Uncertainty ledger

The case's eventual outcome — trial verdict, settlement, or further procedural disposition. Plausible range from substantial damages and structural settlement to a defence verdict.
Whether other behavioural-health subsidiary cases follow the same procedural path. Likely but not guaranteed.
Whether settlement terms (if reached) include structural network-adequacy reform or remain financial. Structural reform is the higher-impact outcome.
Whether the regulatory enforcement environment shifts under the next federal administrative cycle.
The supply-side workforce response. Without provider-rate adjustments and pipeline expansion, even perfect directories cannot solve underlying access shortage.

Bottom Line

A federal judge has just told the commercial mental-health network business that its central representation — that the providers in the directory are providers patients can actually reach — is plausible enough to be tested in court. Whether this case wins or settles, the question of what does your behavioural-health network actually look like has stopped being a quality-improvement metric and started being a legal exposure. The payers, employers, and plan sponsors who treat the next eighteen months as a serious operational reset will avoid being the next defendant. The ones who treat it as the same regulatory backdrop they have managed for fifteen years will not.

Written in the tradition of — P.

Sources

Tier 1. US District Court, Southern District of New York — Carelon ruling on motion to dismiss, 1 April 2026
Tier 1. US Department of Labor, HHS, and Treasury — MHPAEA Final Rule (2024) and accompanying guidance
Tier 1. Mental Health Parity and Addiction Equity Act of 2008 — statutory framework
Tier 2. Bloomberg Law — case coverage and procedural analysis
Tier 2. News-Medical — clinical and policy implications coverage
Tier 1. US Government Accountability Office — historical reports on MHPAEA enforcement
Tier 2. Mental Health America — directory accuracy and parity reports